The Ministry of Health and Welfare has reaffirmed its stance that it will use the health insurance finances saved by the follow-up management measures, including reevaluation of benefit adequacy and reevaluation of the reimbursement standards and conditions, to reimburse drugs that have proven their innovativeness, such as immuno-oncology and targeted-anticancer drugs.

Regarding introducing a differentiated drug pricing system for immuno-oncology drugs by indication in Korea, the NHIS said that more social consensus is needed and that it would first need to gather patients' opinions on paying different prices for the same drug by cancer type and spend the administrative costs required to change the he